Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Avanza Fonder AB

Avanza Fonder AB grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,737 shares of the biopharmaceutical company’s stock after buying an additional 838 shares during the period. Avanza Fonder AB’s holdings in Regeneron Pharmaceuticals were worth $5,112,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Sowell Financial Services LLC raised its position in shares of Regeneron Pharmaceuticals by 4.7% in the second quarter. Sowell Financial Services LLC now owns 583 shares of the biopharmaceutical company’s stock valued at $306,000 after buying an additional 26 shares during the last quarter. CX Institutional raised its position in shares of Regeneron Pharmaceuticals by 7.9% in the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 22 shares during the last quarter. Diversified Trust Co grew its holdings in shares of Regeneron Pharmaceuticals by 35.3% in the second quarter. Diversified Trust Co now owns 3,889 shares of the biopharmaceutical company’s stock valued at $2,042,000 after purchasing an additional 1,015 shares during the period. Kingstone Capital Partners Texas LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $40,736,000. Finally, Grove Bank & Trust grew its holdings in shares of Regeneron Pharmaceuticals by 36.7% in the second quarter. Grove Bank & Trust now owns 1,107 shares of the biopharmaceutical company’s stock valued at $581,000 after purchasing an additional 297 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on REGN shares. UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Citigroup reaffirmed a “buy” rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a research note on Friday, August 1st. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Down 1.1%

REGN stock opened at $591.99 on Friday. The company’s 50 day moving average is $567.77 and its two-hundred day moving average is $575.13. The stock has a market cap of $62.74 billion, a P/E ratio of 14.92, a PEG ratio of 1.98 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,154.56. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $11.56 EPS. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.